Literature DB >> 18849303

Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.

Holly Hagan1, Enrique R Pouget, Don C Des Jarlais, Corina Lelutiu-Weinberger.   

Abstract

The authors examined the relation between time since onset of illicit drug injection (time at risk) and rates of hepatitis C virus (HCV) infection by using meta-regression. In 72 prevalence studies, median time since onset of injection was 7.24 years and median prevalence was 66.02%. The model showed statistically significant linear and quadratic effects of time at risk on HCV prevalence and significantly higher prevalence in developing and transitional countries and in earlier samples (1985-1995). In developed countries post-1995, mean fitted prevalence was 32.02% (95% confidence interval: 25.31, 39.58) at 1 year of injection and 53.01% (95% confidence interval: 40.69, 65.09) at 5 years. In developing/transitional countries post-1995, mean fitted HCV prevalence was 59.13% (95% confidence interval: 30.39, 82.74) at 1 year of injection. In 10 incidence studies, median time at risk was 5.29 years and median cumulative HCV incidence was 20.69%. Mean fitted cumulative incidence was 27.63% (95% confidence interval: 16.92, 41.70) at 1 year of drug injection. The authors concluded that time to HCV infection in developed countries has lengthened. More rapid onset of HCV infection in drug injectors in developing/transitional countries resembles an earlier era of the HCV epidemic in other regions.

Entities:  

Mesh:

Year:  2008        PMID: 18849303      PMCID: PMC2727245          DOI: 10.1093/aje/kwn237

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  88 in total

1.  A certain fate: spread of HIV among young injecting drug users in Manipur, north-east India.

Authors:  A D Eicher; N Crofts; S Benjamin; P Deutschmann; A J Rodger
Journal:  AIDS Care       Date:  2000-08

2.  Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey.

Authors:  A R Weild; O N Gill; D Bennett; S J Livingstone; J V Parry; L Curran
Journal:  Commun Dis Public Health       Date:  2000-06

3.  Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran.

Authors:  Amir Houshang Mohammad Alizadeh; Seyed Moayed Alavian; Khalil Jafari; Nastaran Yazdi
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

4.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

5.  Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users.

Authors:  I Hernandez-Aguado; J M Ramos-Rincon; M J Aviñio; J Gonzalez-Aracil; S Pérez-Hoyos; M G de la Hera
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

6.  Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.

Authors:  R Kemp; J Miller; S Lungley; M Baker
Journal:  N Z Med J       Date:  1998-02-27

7.  Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects.

Authors:  B Galeazzi; A Tufano; E Barbierato; F Bortolotti
Journal:  Liver       Date:  1995-08

8.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity.

Authors:  Markus Backmund; Kirsten Meyer; Martin Wächtler; Dieter Eichenlaub
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

10.  Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression.

Authors:  Peter Bacchetti; Phyllis C Tien; Eric C Seaberg; Thomas R O'Brien; Michael H Augenbraun; Alex H Kral; Michael P Busch; Brian R Edlin
Journal:  BMC Infect Dis       Date:  2007-12-10       Impact factor: 3.090

View more
  100 in total

1.  Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.

Authors:  Desarae Echevarria; Alexander Gutfraind; Basmattee Boodram; Jennifer Layden; Jonathan Ozik; Kimberly Page; Scott J Cotler; Marian Major; Harel Dahari
Journal:  Vaccine       Date:  2019-04-05       Impact factor: 3.641

2.  Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City.

Authors:  Kelly Quinn; Chunki Fong; Honoria Guarino; Pedro Mateu-Gelabert
Journal:  Drug Alcohol Depend       Date:  2018-11-28       Impact factor: 4.492

3.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

4.  Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study.

Authors:  Jenny Iversen; Handan Wand; Libby Topp; John Kaldor; Lisa Maher
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

5.  Hepatitis C virus serosorting in people who inject drugs: sorting out the details.

Authors:  Arthur Y Kim; Kimberly Page
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

6.  Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.

Authors:  Jason Grebely; Sarah Larney; Amy Peacock; Samantha Colledge; Janni Leung; Matthew Hickman; Peter Vickerman; Sarah Blach; Evan B Cunningham; Kostyantyn Dumchev; Michael Lynskey; Jack Stone; Adam Trickey; Homie Razavi; Richard P Mattick; Michael Farrell; Gregory J Dore; Louisa Degenhardt
Journal:  Addiction       Date:  2018-08-28       Impact factor: 6.526

7.  The Interaction of Risk Network Structures and Virus Natural History in the Non-spreading of HIV Among People Who Inject Drugs in the Early Stages of the Epidemic.

Authors:  Kirk Dombrowski; Bilal Khan; Patrick Habecker; Holly Hagan; Samuel R Friedman; Mohamed Saad
Journal:  AIDS Behav       Date:  2017-04

Review 8.  Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies.

Authors:  Ashley B Pitcher; Annick Borquez; Britt Skaathun; Natasha K Martin
Journal:  J Theor Biol       Date:  2018-11-16       Impact factor: 2.691

9.  Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment.

Authors:  Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate
Journal:  Drug Alcohol Depend       Date:  2019-09-04       Impact factor: 4.492

10.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.